# IMHOTEP (NCT04795661)

> Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: localized resectable MSI/dMMR tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04795661
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Centre Leon Berard
- Conditions: Localized Resectable Tumor; MSI/dMMR
- Interventions: Pembrolizumab
- Enrollment: 240
- Primary outcome: Rate of complete pathological response (pCR) after surgery

## Indexed commentary on IMHOTEP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 28
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imhotep-nct04795661

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04795661", "email": "<work email>"}; the inbox owner confirms by the emailed link.